Tecentriq® (atezolizumab) - Risk Of Immune-related Nephritis

Tecentriq (atezolizumab), a cancer treatment drug, is being recalled across Canada due to a risk of immune-related kidney inflammation (nephritis). This condition can develop in patients taking the medication. The recall affects all batches of this drug distributed throughout Canada.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2018-09-18

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/fbc6805a-a3df-4887-a97d-89a694310349